Literature DB >> 11377525

Phase III trial of Rapamune versus placebo in primary renal allograft recipients.

C Ponticelli1, A S MacDonald, P Rajagopalan, R Sindhi, T Mathew.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11377525     DOI： 10.1016/s0041-1345(01)01987-x

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  4 in total

1.  Should diabetic women with breast cancer have their own intervention studies?

Authors:  David A Potter; Douglas Yee; Zhijun Guo; Mariangellys Rodriguez
Journal:  Endocr Relat Cancer       Date:  2012-02-13       Impact factor: 5.678

Review 2.  Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.

Authors:  Mona Khurana; Douglas M Silverstein
Journal:  Pediatr Nephrol       Date:  2015-03-24       Impact factor: 3.714

3.  Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.

Authors:  Deirdre Hahn; Elisabeth M Hodson; Lorraine A Hamiwka; Vincent Ws Lee; Jeremy R Chapman; Jonathan C Craig; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2019-12-16

4.  Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.

Authors:  Haeseong Park; Ignacio Garrido-Laguna; Aung Naing; Siqing Fu; Gerald S Falchook; Sarina A Piha-Paul; Jennifer J Wheler; David S Hong; Apostolia M Tsimberidou; Vivek Subbiah; Ralph G Zinner; Ahmed O Kaseb; Shreyaskumar Patel; Michelle A Fanale; Vivianne M Velez-Bravo; Funda Meric-Bernstam; Razelle Kurzrock; Filip Janku
Journal:  Oncotarget       Date:  2016-10-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.